A series of novel diketoquinoline acid derivatives as potential anti-HIV-1 Integrase inhibitors were docked, synthesized and characterized by IR, NMR , CHN and MS spectral analysis. Many compounds were identified and docked in integrase pocket. The target diketoquinolines were prepared from substituted oxoquinoline-3-carboxylate. In vitro biological evaluation revealed that some of the titled compounds exhibited moderate to good anti-HIV-1 Integrase inhibitory activity in comparison with the reference drugs i.e. raltegravir and nevirapine. The cytotoxicity of most of testing compounds on C8166 were very low, the CC50 value of them were higher than 200 μM, except the few compounds. Compounds 1-5 showed weak anti-HIV-1 activity, its therapeutic index was 457, 531, 583, 869 and 909 respectively. As a positive control drug, Nevirapine has the best anti-HIV-1 activity (EC50 = 0.015-0.016 μM) in vitro and the CC50 of was higher than 200 μM, its therapeutic index was higher 12418.50. In integrase assay compound 6 and 7 showed EC50 value 0.08 μM as compared with standard drug raltegravir.
一系列新颖的二酮
喹啉酸衍
生物被设计为潜在的抗HIV-1整合酶
抑制剂,经过对接、合成和通过红外、核磁共振、元素分析和质谱谱分析进行表征。许多化合物被鉴定并对接到整合酶口袋中。目标二酮
喹啉酸衍
生物是从取代的氧
喹啉-3-羧酸酯制备而来的。体外
生物评价表明,一些标题化合物与参考药物即拉替尼韦和
奈韦拉平相比,表现出中等至良好的抗HIV-1整合酶抑制活性。大多数测试化合物对C8166的细胞毒性很低,它们的CC50值高于200μM,除了少数化合物。化合物1-5显示出较弱的抗HIV-1活性,其治疗指数分别为457、531、583、869和909。作为阳性对照药物,
奈韦拉平在体外表现出最佳的抗HIV-1活性(
EC50 = 0.015-0.016μM),其CC50值高于200μM,治疗指数高达12418.50。在整合酶测定中,化合物6和7的
EC50值为0.08μM,与标准药物拉替尼韦相比。